Blog Posts - BioPharmaSpec

Understanding the “interchangeable” biosimilar designation

Friday 17th November 2023

Hunting Host Cell Proteins (HCPs) with Mass Spectrometry

Tuesday 31st October 2023

Process Related Impurities: Looking Beyond the API for Safer Biotherapeutics

Friday 29th September 2023

Using Glycan Data to Predict Functionality and Shape PK Studies

Thursday 24th August 2023

BioPharmaSpec – a fully integrated extension of your analytical capabilities

Monday 10th July 2023

Amino Acid Analysis: an essential technique for the analytical lab

Friday 16th June 2023

Higher Order Structure and Aggregation Analysis of Antibody Drug Conjugates (ADCs)

Wednesday 3rd May 2023

Being BioPharmaSpec Newbies: Experiences Gained in Our First 9 months

Wednesday 26th April 2023

Intact Mass: A Simple Analysis?

Tuesday 14th March 2023

Q&A Session with Biosimilar Roundtable Panelists – Dr Andrew Reason

Friday 24th February 2023

Glycosylation in Plants- a barrier to Plant Molecular Farming (PMF)?

Thursday 12th January 2023

Considerations for the Analysis of Glycans from Different Cell Types

Tuesday 20th December 2022

Evolution of ICH Q2 guideline (Validation of Analytical Procedures)

Tuesday 29th November 2022

Analytical Quality by Design – What’s it all about?

Thursday 27th October 2022

Knowledge-based Structural Analysis of Biopharmaceuticals

Wednesday 28th September 2022

Q&A Session with Biosimilar Roundtable Panelists – Dr. Dan Mamelak

Tuesday 23rd August 2022

Q&A Session with Biosimilar Roundtable Panelists – Dr Marius Schmid

Tuesday 23rd August 2022

Q&A Session with Biosimilar Roundtable Panelists – Dr Richard Easton

Tuesday 23rd August 2022

Q&A Sessions with Biosimilar Analytical Experts

Monday 22nd August 2022

O- Glycan Characterization: small but mighty glycans!

Wednesday 17th August 2022

The Synergy of Structural and Functional Analysis in Biosimilar Development

Friday 15th July 2022

The Need for Orthogonal Methods in Higher Order Structure (HOS) Analysis

Thursday 30th June 2022

Should methods be qualified for biosimilar structural characterization?

Friday 27th May 2022

Forced Degradation Studies: Why, What and How

Friday 29th April 2022

Connecting Scientific Expertise and Data Processing Software

Wednesday 9th March 2022

The Case for Orthogonal Aggregation Analysis

Thursday 3rd February 2022

Structural Analysis of Novel Chemistries

Wednesday 19th January 2022

CE-SDS: Old Dog, New Tricks?

Wednesday 19th January 2022

Oligonucleotide-based Drugs: a Promising Class of New Therapeutics?

Thursday 2nd December 2021

Thinking About LC-MS for HCP Quantitation?

Tuesday 23rd November 2021

Analysis of Adeno-Associated Virus (AAV) Capsid Proteins

Friday 13th August 2021

Two Steps Forward for Biosimilars in the US: The Approval of Interchangeable Semglee®

Wednesday 11th August 2021

“Gene Therapy – Game changer treatments” – Dr. Fiona Greer

Friday 4th June 2021

Guest blog: “US FDA Biosimilar Regulatory Developments in 2020”- Dr. Fiona Greer

Thursday 1st April 2021

Dealing with the Challenges of Disulfide Bridge Analysis in Biopharmaceuticals

Wednesday 17th March 2021

Guest blog: “A Brexit Bonus for Biosimilars in the UK?” – Dr. Fiona Greer

Thursday 21st January 2021

Dealing with the challenges of N-glycan structures in complex glycoproteins

Wednesday 13th January 2021

Guest Blog: “Analytical R&D: Thoughts on Outsourcing vs In-house” – Dr. Fiona Greer

Wednesday 13th January 2021

Building Orthogonality into Your Analytical and Characterization Plans – Part 2

Friday 20th March 2020

Building Orthogonality into Your Analytical and Characterization Plans – Part 1

Monday 24th February 2020

Biosimilar Testing: Structural and Physico-Chemical Comparability Analysis

Thursday 30th January 2020

Protein Characterization Services to Support the Development of New Biopharmaceutical Products

Friday 13th December 2019